Comparison Guide
Semaglutide vs Retatrutide: Single Agonist vs Triple Agonist
Semaglutide revolutionized metabolic research as the most clinically validated GLP-1 agonist. Retatrutide represents the next evolution — the first triple-receptor agonist. This guide compares their mechanisms, clinical data, and what the receptor evolution means for research.
Bottom line: Semaglutide (CAS 910463-68-2) is a GLP-1 single-receptor agonist with 16.9% mean weight loss in STEP trials, proven cardiovascular benefit (20% CV risk reduction in SELECT), and full FDA approval. Retatrutide (CAS 2381089-83-2) is a GLP-1/GIP/glucagon triple agonist with 24.2% weight loss in Phase 2 (up to 28.7% in TRIUMPH-4) — the highest ever reported. Retatrutide's glucagon receptor activation adds direct energy expenditure and hepatic fat oxidation that Semaglutide cannot provide. Semaglutide has more clinical data; Retatrutide has stronger efficacy data but is still in Phase 3 trials.
Head-to-Head Comparison
| Property | Semaglutide | Retatrutide |
|---|---|---|
| CAS Number | 910463-68-2 | 2381089-83-2 |
| Developer | Novo Nordisk | Eli Lilly |
| Receptor Targets | GLP-1 only | GLP-1 + GIP + Glucagon |
| Agonist Type | Single | Triple |
| Amino Acids | 31 | 39 |
| Half-Life | ~7 days | ~6 days |
| Dosing | Once weekly | Once weekly |
| Peak Weight Loss | 16.9% (STEP 1) | 24.2% Phase 2, 28.7% TRIUMPH-4 |
| CV Outcome Data | Yes — SELECT (20% risk reduction) | In progress |
| FDA Approval | Yes (Wegovy, Ozempic) | Phase 3 (TRIUMPH program) |
| Unique Mechanism | Appetite suppression + gastric slowing | Adds glucagon-driven energy expenditure + liver fat oxidation |
| Annual Revenue | $40B+ (2025) | N/A (pre-approval) |
📊 The Receptor Evolution: Why More Targets Matter
The fundamental difference between Semaglutide and Retatrutide is the number of receptor targets — and each additional receptor unlocks new metabolic mechanisms:
GLP-1 Receptor (both)
Appetite suppression, delayed gastric emptying, improved insulin secretion. The foundation shared by both compounds.
GIP Receptor (Retatrutide only)
Enhanced insulin sensitivity, adipose tissue remodeling, and amplified GLP-1 effects through receptor crosstalk.
Glucagon Receptor (Retatrutide only)
Direct energy expenditure increase, hepatic fat oxidation, and thermogenesis. This "calorie burning" effect is unique to triple agonists and not present in Semaglutide.
In short: Semaglutide makes you eat less. Retatrutide makes you eat less and burn more — explaining the substantial difference in weight loss outcomes.
Where Semaglutide Still Leads
STEP, SUSTAIN, PIONEER, and SELECT trials with 30,000+ participants. The most clinically validated peptide in metabolic research history.
SELECT trial demonstrated 20% reduction in major adverse cardiovascular events — the first obesity drug with proven CV benefit.
Approved since 2017 (Ozempic) and 2021 (Wegovy). Years of real-world safety data across millions of patients.
Rybelsus is the first oral GLP-1 agonist — no injection needed. No oral Retatrutide exists.
